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Introduction
Diabetes mellitus is defined as a heterogeneous metabolic disorder that clinically manifested by 
chronic hyperglycemia due to either impaired insulin secretion or defect in insulin action or both 
[1]. According to World Health Organization, diabetes mellitus is classified as one of four common 
major types of non-communicable disease worldwide. In 2014, it was estimated that 422 million 
adults around the world were diagnosed with diabetes, and in 2012, 1.5 million people died because 
of it (World Health Organization, 2016) [2]. Type 2 diabetes is more prevalent than type 1 [1]. The 
diagnosis of diabetes must be based on plasma-glucose values of Fasting Plasma Glucose (FPG) 
that are equal to or greater than 126 mg/dL (7.0 mmol/L), or 2-h plasma-glucose values during a 75 
g oral glucose-tolerance test that are equal to or greater than 200 mg/dL (11.1 mmol/L) or an A1c 
Hemoglobin blood test (HbA1c) that is equal to or greater than 6.5% (48 mmol/mol) [3].
Duration of diabetes and intensity of hyperglycaemia are the main leading factors for the 
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Abstract
Background: The aim of this systematic review is to examine the effectiveness of Liraglutide on 
glycemic control and Systolic Blood Pressure (SBP) in patients with Type 2 Diabetes (T2D) mellitus 
and to investigate whether Liraglutide leads to any Gastrointestinal (GI) adverse effects.
Materials and Methods: seven databases were searched, including CINAHL, MEDLINE, PubMed, 
EMBASE, Cochrane, Joana Briggs Institute (JBI). Only Randomized Controlled Trials (RCTs) 
that assessed safety and efficacy of Liraglutide in patients with type 2 diabetes were included. The 
extracted outcome measures were HbA1c, SBP, and GI disturbances.
Results: 40 RCTs were included with overall numbers of participants were 16,113. Liraglutide as 
monotherapy or as adjunct treatments to other diabetes treatments showed significant reduction in 
HbA1c levels in patients with T2D. Nine studies compared Liraglutide to a placebo and Liraglutide 
was superior to the placebo at HbA1c reduction. Four studies compared Liraglutide to Sitagliptin, 
five to Glimepiride, and one to Rosiglitazone, in these studies Liraglutide was also superior at HbA1c 
reduction. Two studies compared it to Metformin, in one of them Liraglutide was superior. One 
study compared Liraglutide to variety of Oral Anti-Diabetes Medications (OADs); Liraglutide was 
superior at HbA1c reduction. Ten studies compared Liraglutide to variety of insulin therapy, the 
combination of Liraglutide plus Insulin showed greater reduction at HbA1c levels than Liraglutide 
or Insulin alone. In addition, Liraglutide was superior when compared to insulin as part and 
insulin glargine at HbA1c reduction. Eight studies compared Liraglutide to glucagon-like peptide-1 
receptor agonist (Exenatide, Dulaglutide, Lixisenatide, Albiglutide, and Semaglutide), Liraglutide 
was superior to Exenatide, Lixisenatide, and Albiglutide at HbA1c reduction. In most of the included 
studies Liraglutide showed significant reduction in SBP. Liraglutide can lead to different GI events, 
most frequently nausea, vomiting, and diarrhea, which are transient in nature.
Conclusion: The results of this systematic review indicated that Liraglutide as a monotherapy or 
as adjunct treatments to other diabetes treatments could significantly lower HbA1c levels and SBP. 
Although the gastrointestinal adverse event is common with Liraglutide, Liraglutide can be effective 
choice in T2D treatment.
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development of diabetes complication [4]. Diabetes complications 
are divided into microvascular complications, which is due to 
damage to the small blood vessels and macrovascular complication 
that due to damage to larger blood vessels [4,5]. Examples of 
microvascular complications include 1) Diabetes retinopathy; 2) 
Diabetes nephropathy 3) Diabetes neuropathy and macrovascular 
complications.
The principal goal of diabetes treatment is to maintain glycemic 
control by implementing various lifestyle changes and undergoing 
pharmacological therapy [6]. There are many classes of drugs available 
for the treatment of type 2 diabetes, including alpha-glucosidase 
inhibitors, thiazolidinediones and Glucagon-Like Peptide-1 (GLP-1) 
receptor agonists [6,7]. However, the first choice for the treatment of 
type 2 diabetes is metformin [7-9]. If the target blood-glucose levels 
are not achieved within three months through the use of metformin, 
a second drug combination will be used [9].
Liraglutide
Liraglutide (Victoza®) is an injectable synthetic analogue of 
human Glucagon-Like Peptide-1 (GLP-1) that works as GLP-1 
receptor agonist [10]. Liraglutide shares 97% amino acid homology 
to the amino acid structure of native Human GLP-1 [10-12]. This 
was obtained by substitution of lysine at position 34 to arginine 
34 at N-terminal and addition of 16-carbon fatty-acid chain using 
a glutamic acid spacer that is chemically attached to the lysine at 
position 26 [11-12]. These changes prolonged the plasma half-life of 
Liraglutide to 13 hours compared to human GLP-1 half-life, which is 
~2 min [11-12].
GLP-1 is gut-derived hormone produced by enteroendocrine 
L-cells in the distal ileum of the large intestine; the primary stimulus 
for GLP-1 secretion is food ingestion [13]. The most common action 
of GLP-1 is on islet beta cells as the effect of GLP-1 receptor activation 
leads to insulin secretion in glucose-dependent manner [14]. The 
glucoregulatory actions of GLP-1 is exhibited via slowing of gastric 
emptying; inhibition of glucagon secretion; promoting satiety, which 
is associated with weight reduction in both preclinical and clinical 
studies [13].
Liraglutide has similar effects of GLP-1 but with prolonged half-
life of 13 h and maximum concentration reached after 8 h to 12 h 
of subcutaneous administration [11]. When blood-glucose levels 
are elevated, Liraglutide stimulates GLP-1 receptors to release 
insulin, reduce glucagon secretion and inhibit gastric emptying, 
thus leading to increased control of body weight [10]. This mode of 
glucose-dependent action is also associated with lower instances of 
hypoglycemic episodes [15].
Liraglutide was approved by the US Food and Drug 
Administration in January 2010 to improve glycemic control in type 2 
diabetes mellitus in addition to when coupled with a balanced diet and 
exercise [13,16]. Liraglutide is an once-daily subcutaneous injection 
that can be injected at any time of the day, independently of meals 
[17]. It is available as 0.6 mg, 1.2 mg and 1.8 mg, the initiation dose is 
0.6 mg and after week increase to 1.2 mg then it can be increased to 
1.8 mg for more efficiency [17].
Liraglutide also leads to various other non-glycemic benefits 
such as improvement in systolic blood pressure and the functioning 
of β-cells [18]. A randomized controlled double-blind study of 
9,340 patients over 3.8 years assessed the effect of Liraglutide on 
the cardiovascular outcome. It concluded that the rate of non-fatal 
myocardial infarction, non-fatal stroke or the occurrence of first 
death due to cardiovascular causes in type 2 diabetes patients was 
lower in patients receiving Liraglutide than placebo [19]. Liraglutide 
also assists with weight loss, especially for overweight and obese 
patients with type 2 diabetes [20]. The efficiency of Liraglutide in 
weight management was investigated in randomized clinical trial 
of 846 overweight diabetes patients. Patients were randomized to 
receive 1.8 mg Liraglutide (n=211), 3.0 mg Liraglutide (n=423), or 
placebo (n=212). The results show weight loss of 6.0% with 3.0 mg 
Liraglutide, 4.7% weight loss with 1.8 mg Liraglutide and 2.0% with 
placebo [20]. These features of GLP-1 receptor agonists have made 
them an attractive choice for patients with type 2 diabetes [15].
Multiple studies have assessed the efficacy and safety of 
Liraglutide. The Liraglutide Effect and Action in Diabetes (LEAD) 
program, which was founded by the manufacturer of Liraglutide, 
Novo Nordisk, consisted of six Randomized Controlled Trails (RCT) 
that assess the effect of Liraglutide as a form of monotherapy or in 
combination with other anti-diabetes drugs. In LEAD program, 
3,900 patients were recruited from forty countries [11]. An overview 
of LEAD studies concluded that from the LEAD-1 to LEAD-5 trials, 
Liraglutide led to a reduction in HbA1c by up to 1.6%, a rapid 
reduction in FPG and a consistent reduction in postprandial glucose. 
Liraglutide was also associated with significant weight loss, reduced 
the risk of hypoglycemia and reduced systolic blood pressure [21].
No large scale systematic review has previously investigated the 
effectiveness and safety of Liraglutide itself. 
The aim of this systematic review is to examine the effectiveness 
of Liraglutide on glycemic control and Systolic Blood Pressure (SBP) 
in patients with type 2 diabetes mellitus and to investigate whether 
Liraglutide leads to any gastrointestinal adverse effects.
Materials and Methods
Eligibility criteria
Participants: This systematic review considered RCTs that 
include adults over the age of 18 with type 2 diabetes mellitus who 
have inadequate control of their blood-glucose levels. Patients were 
excluded if they presented with conditions that affect their red blood 
cells, such as anemia or end-stage kidney disease, or patients who 
have recently undergone a blood transfusion.
Intervention
This systematic review considered studies that evaluated the 
effectiveness of Liraglutide as a combination to one or more other 
diabetes treatment (i.e., metformin, sulfonylurea, Pioglitazone, DPP-
4 inhibitors, Glinides and insulin) or as a monotherapy in lowering 
blood-glucose levels and SBP. The key intervention of interest was 
the administering of Liraglutide. Any dosages of Liraglutide were 
considered in the review.
Study type
This systematic review considered only RCTs that investigated 
the effectiveness of Liraglutide in hyperglycemic control, SBP and GI 
adverse events.
Comparison
The effect of administering Liraglutide compared to placebo, 
metformin, insulin, Glucagon-like peptide-1 receptor agonist, 
Dipeptidyl peptidase-4 inhibitors or any other antidiabetes 
medications.
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Primary outcomes
The primary outcome is to measure the effect of Liraglutide in 
lowering blood-glucose levels. All included studies assess this effect 
by measuring HbA1c in order to ensure homogeneous data for a 
reliable analysis.
Secondary outcomes
Systolic blood pressure: This secondary outcome is to assess the 
effectiveness of Liraglutide in lowering systolic blood pressure.
Gastrointestinal disturbance
This secondary outcome is to evaluate any gastrointestinal 
adverse events associated with Liraglutide.
Search strategy
First stage: An initial basic search of PubMed, CINAHL and 
EMBASE using the basic search words and phrases (i.e., Liraglutide, 
type 2 diabetes and glycemic control) was done to find potentially 
relevant studies with no specific time frame. After reviewing the title 
and abstract of these initial studies, the search words and phrases 
were expanded.
Second stage: Databases and grey literature sources were searched 
using the identified keywords and phrases. These databases included: 
CINAHL, MEDLINE, PubMed, EMBASE, Cochrane, Joana Briggs 
Institute (JBI). The grey literature included: American Diabetes 
Association, International Diabetes Federation, and Google Scholar.
Third stage: The reference lists of the identified studies also 
were examined. A search of authors’ names who are known to have 
conducted research in the same field also were carried out in order to 
find more relevant studies.
Study selection
The titles and abstracts of the studies were examined during the 
search process and some studies full texts were examined for more 
details. The RCTs that met the inclusion criteria were included and 
studies that did not meet the inclusion criteria were excluded as well 
the duplicated studies.
Critical appraisal
All included studies were critically appraised for their 
methodological validity before being including in the review. Critical 
appraisal instruments were used from the Joanna Briggs Institute.
All RCTs in this systematic review were assessed for bias and 
judged according to high, low or unclear levels of bias, based on the 
Cochrane risk-of-bias tool criteria. The five elements of bias (i.e., 
selection, performance, attrition, detection and reporting bias) were 
assessed using this tool.
Selection bias: This can happened due to inadequate generation 
of randomized sequence or inadequate concealment of allocations 
before the assignment. All included studies were given either ‘Low 
Risk’ of bias if the study describe the way of randomized sequence 
generation and concealment of allocations or ‘Unclear Risk’ of bias 
if the study does not describe the way of randomized sequence 
generation and concealment of allocations. ‘High Risk’ of bias was 
given if the study did not perform the allocation concealment.
Performance bias: Can happen due to participant and personal 
knowledge of intervention allocation. All included studies were given 
either ‘Low Risk’ of bias if the study was double blinded and/or double 
dummy or ‘High Risk’ of bias if the study was not blinded.
Detection bias: This can happen due to outcome assessor 
knowledge of the allocated intervention. In all included studies this 
domain was not addressed by authors thus it was deleted from the 
figure chart.
Attrition bias: this can happened due to the way of dealing with 
incomplete data. All included studies were given either ‘Low Risk’ of 
bias if the study explained the way they handled incomplete data ( 
most studies imputed the missing values by last observation carried 
forward), or ‘High Risk’ of bias if the study stated that they did not 
imputed the missing  values, or ‘Unclear Risk’ if they did not mention 
anything about it.
Reporting bias: can happen due to selective reporting. All 
included studies were given either ‘Low Risk’ of bias if there is a 
protocol or clear listed outcome, or ‘Unclear Risk’ of bias if there was 
no protocol but clear listed outcome.
Other bias: In this review other bias is referred to the nature of 
funding that support the study as this medication is manufactured by 
Novo Nordisk Company that funded most of the included studies.
Data extraction and synthesis
Each included study was summarised and necessary details 
extracted using the Joanna Briggs Institute data extraction form.
Study method, type of participant, setting (i.e., where the study 
was done, sample size and interventions), in what dose Liraglutide 
was administered, was the participant on other medication such 
as metformin or sulfonylurea or insulin etc, the primary outcome 
measure of HbA1c, the secondary outcome measures of systolic 
blood pressure and the gastrointestinal adverse events (e.g., nausea, 
diarrhea, vomiting, decreased appetite or headache) and authors’ 
conclusions.
Results
Search results: Seven electronic databases identified 1,679 
studies: CINAHL (n=25), MEDLINE (n=469), PubMed (n=338), 
EMBASE (n=413), Cochrane (n=429), Joana Briggs Institute (JBI) 
(n=5).  Initially, all the studies were assessed by title alone. If the 
titles were found to be relevant, the abstracts were then assessed for 
eligibility then a full text analysis was carried out. 552 duplicates were 
removed and 1,073 irrelevant studies were excluded after title and 
abstract review. Full text examination of the remaining 54 studies 
based on the inclusion and exclusion criteria and forty studies met 
the review inclusion criteria. Figure 1 shows PRISMA flow diagram 
of the studies identification.
Excluded studies: Fourteen studies were excluded out of 54 
studies after full text analysis due to: (n:2) studies the participants age 
was less than 18 years old; (n:1) study the participants with type 1 
diabetes millets; (n:3) studies were assessing the efficacy and safety 
of switching from some types of medication to Liraglutide which 
can interfere with the study's results; (n:1) study short duration of 
intervention (5 weeks); (n:1) study analysis of three RCTs (LEAD 1, 
LEAD 2 and LEAD 4).
Characteristics of included studies: All the included studies 
are Randomized Control Trials. The publication date of included 
studies ranged from 2004 to 2016. Half of the included trials (n:20) 
are multinational; (n:7) were carried out in Japan; (n:5) in USA; (n:3) 
in China; (n:1) in Netherlands; (n:1) in Sweden; (n:1) in Germany; 
(n:1) in Scandinavia and UK; and one study did not mention the 
origin (Feinglos et al, 2004). Most of the trials (n:35) are multicentre 
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and the remaining are single-centre except in (Feinglos et al, 2004). 
The duration of the RCTs ranged from 8 weeks to 104 weeks: (n:17) 
studies for 26 weeks; (n:6) studies for 52 weeks; (n:6) studies for 24 
weeks; (n:3) studies for 12 weeks; (n:2) studies for 16 weeks; (n:2) 
studies for 14 weeks; (n:1) study for 8 weeks; (n:1) study for 32 weeks; 
(n:1) study for 36 weeks; (n:1) study for 104 weeks.
See Table 1 for the summary of the studies characteristics.                                
Characteristics of participants: In all the trials, the overall 
number of participant is 16,113 with studies sample size ranged from 
37 subjects to 1,663 subjects. Participants are aged 18 years old and 
above with mean age ranged between 52.0 ± 10.2 years and 61.8 ± 8.2 
years. All the participants with type 2 diabetes and the mean duration 
of the disease ranged from 2.6 ± 2.9 years to 17.9 ± 8.4 years. All trials 
included both male and female subjects with varying percentages 
among studies. Mostly, each included study has a number of patients 
discontinuing the trial due to the side effect of Liraglutide, the number 
of participant and completers in each study (Table 1) [22-61].
Characteristics of intervention: The main intervention in all 
included studies is administering Liraglutide. The predominant doses 
of Liraglutide in most of the trials are: 0.6 mg, 1.2 mg or 1.8 mg all per 
day. Three studies were dose findings in which they used less doses 
[62].
Risk of bias in included studies: The Cochrane Collaboration’s 
tool for assessing risk of bias consists of six domains: Selection bias, 
performance bias, detection bias, attrition bias, reporting bias, and 
other bias [63]. Each domain were assessed by answering pre-specified 
questions and the level of bias expressed by ‘Low Risk’, ‘High Risk’ 
and ‘Unclear Risk’ (Figure 2).
Results and Discussion
The aim of this review was to assess the efficacy of Liraglutide in 
lowering HbA1c levels among type 2 diabetes patients as a primary 
outcome and its efficacy on SBP as a secondary outcome, as well as 
any associated GI disturbances. The results show that Liraglutide is 
effective on both HbA1c and SBP and that it can lead to various GI 
disturbances.
Theme 1: Liraglutide and HbA1c
The HbA1c level was the primary outcome measure of all 
included studies. The studies’ results advocate Liraglutide’s use as 
an effective treatment management of type 2 diabetes. In 16 of the 
studies (10, 11, 12, 14, 16, 19, 22, 24, 26, 27, 28, 32, 33, 37, 38, and 
40), the interventions comprised multiple arms, including different 
dosages of Liraglutide and the comparator. In these trials, it is shown 
Figure 1: PRISMA flow diagram of studies identification.
Figure 2: Summary of risk of bias in included studies (RevMan 5.3). (Key: (+) 
Low risk of bias, (-) High risk of bias, (?) Unclear risk of bias).
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 Author Study type Study duration Participant Intervention 
Background 
medication 
Outcomes
1 Ahmann et al. [22]
RCT Multicenter 
Multinational 
Double-blind
26 weeks
· 450 Pts randomized
· Liraglutide: 1.8 mg/
day. (pts number 225)
Basal insulin analogue 
(≥ 20 U/day) ± 
metformin (≥ 1500 
mg/day).
1. HbA1c:  
· 364 Pts completed Before: mean SD 8.25% ± (0.85%)  
· Male: 56.8% 7.0% to 10.0%  
· Female: 43.2% After Liraglutide: estimated change -1.3%  
·T2D duration: 12.1 ± 
6.9 Years
After placebo: estimated change -0.1%  
2. SBP:  
· Placebo: (pts number 
225)
After Liraglutide: -5.78 mmHg ↓ from baseline.  
After placebo: -0.76 mmHg ↓ from baseline.  
3. GI events:  
Number of patients reporting GI events in each group:  
 Liraglutide placebo  
Nausea 50 7  
·Mean (SD) Age: 58.4 
± 10.1.
Diarrhea 24 11  
Vomiting 20 2  
Dyspepsia 16 2  
Nasopharyngitis 13 14  
Headache 8 16  
Lipase increased 17 5  
Decreased appetite 22 5  
2 Aroda et al. [23]
RCT Multicenter 
Multinational 
Double-blind
26 weeks+15 
weeks run-in 
period
·346 Pts randomized
·Liraglutide 1.8 mg/
day + Placebo. (pts 
number 172)
Metformin (≥ 1500 mg)
1. HbA1c:  
Before: mean SD 7.6 ± 0.6%  
After Liraglutide 1.8 mg/day + Insulin Degludec: estimated 
change -1.04% from baseline 
 
 · 291 Pts completed
After Liraglutide 1.8 mg/day + Placebo: estimated change 
-0.16% from baseline
 
 
 
 
· Liraglutide 1.8 
mg/day + Insulin 
Degludec. (pts number 
174)
· Male: 58.4%
· Female: 41.6%
2. SBP:  
From week 0 to week 26, mean blood pressure decreased slightly 
in both treatment groups.
 
3. GI events:  
Number of patients reporting GI events in each group:  
·T2D duration
 
Liraglutide 
1.8 mg/day + 
Placebo
Liraglutide 1.8 
mg/day + Insulin 
Degludec
 
Diarrhea 13 10  
· Mean(SD): 9.5 ± 5.6 
Years
Nasopharyngitis 11 14  
Lipase increased 13 10  
· Mean(SD)Age:57.1 ± 
9.7 years
 
 
Table 1: Summary of the included studies result.
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3 Buse et al. [24]
RCT Multicenter 
Multinational open-
label
26 weeks
·464 Pts randomized
· Liraglutide 1.8 mg/
day: (pts number 233
 
 
Maximum dose 
of metformin, 
sulphonylurea, or both.
1. HbA1c:  
Before: mean SD 8.2 ± 1.0%  
After Liraglutide 1.8 mg/day: estimated change -1.12% from 
baseline 
 
· 389 Pts completed After Exenatide 10 μg twice a day: estimated change -0.79% 
from baseline 
 
 
· Male: 52%
· Exenatide 10 μg 
twice a day: pts 
number 231 
 
 
 
 
 
 
 
 
· Female: 48%
2. SBP:  
After Liraglutide 1.8 mg/day: -2.51 mmHg ↓ from baseline.  
After Exenatide 10 μg twice a day: -2.0 mmHg ↓ from baseline.  
· T2D duration
3. GI events:  
Number of patients reporting GI events in each group:  
 Liraglutide Exenatide  
Nausea 60 65  
Mean (SD): 8.2 ± 6.0 
Years
Diarrhea 29 28  
Vomiting 14 23  
 Dyspepsia 21 11  
 Nasopharyngitis 27 31  
· Mean(SD)Age:56.7 ± 
10.3 years
 Headache 21 24  
 Constipation 12 6  
4 Buse et al. [25]
RCT Multicenter 
Multinational open-
label
26 weeks
·911 Pts randomized · Liraglutide: 1.8 mg/
day. (pts number 450)
maximum or near 
maximum dose of oral 
antihyper- glycaemic 
drugs (metformin, 
sulfonylurea, metformin 
plus sulfonylurea, 
or metformin plus 
pioglitazone)
1. HbA1c:  
Before: mean SD 8.45 ± 1.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After Liraglutide: estimated change -1.48%
·791 Pts completed
After Exenatide: estimated change -1.28% 
 
· Exenatide: 2 mg/
week (pts number 461)
2. SBP: 
· Male: 54.5%
After Liraglutide: -3.45 mmHg ↓ from baseline. 
After Exenatide: -2.48 mmHg ↓ from baseline. 
 
· T2D duration: 8.5± 6 
Years
3. GI events:
Number of patients reporting GI events in each group: 
 Liraglutide Exenatide
Nausea 93 43
· Mean(SD)Age: 57± 
9.5 years
Diarrhea 59 28
Vomiting 48 17
Dyspepsia 27 11
Nasopharyngitis 32 31
Headache 38 27
Decreased appetite 29 17
Constipation 22 21
Abdominal pain 8 12
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5
Charbonnel et 
al. [26]
RCT Multicenter 
Multinational open-
label
26 week
· 653 Pts randomized
· Liraglutide: 1.2 mg/
day. (pts number 253)
metformin 
monotherapy ≥ 1,500 
mg/day
1. HbA1c:  
Before: baseline 7.0-11.0%, mean SD 8.15 ± 1.0%  
After Liraglutide: estimated change -1.4% ↓ from baseline  
·532 Pts completed
After Sitagliptin: estimated change -1.3% ↓ from baseline.  
· Sitagliptin: 100 mg/
day (pts number 269)
  
2. SBP:  
· Male: 55% After Liraglutide : -1.9 mmHg ↓ from baseline  
 
· T2D duration: 7.9 ± 5.5 
Years
After Sitagliptin: 0.9 mmHg ↓ from baseline  
  
Number of patients reporting GI events in each group:  
 Liraglutide Sitagliptin  
 · Mean(SD)Age: 57 ± 
10.4 years
 
 
Nausea 63 10  
Diarrhea 35 7  
Vomiting 21 6  
Dyspepsia 11 4  
Constipation 6 4  
Abdominal pain 16 5  
6 DeVries et al. [27]
RCT Multicenter 
Multinational open-
label
26 weeks 
 
· 323 Pts randomized
· Liraglutide: 1.8 mg/
day. (pts number 161)
metformin (≥ 1500 
mg/day)
1. HbA1c:  
Before: mean SD 8.25 ± 0.75%  
12 weeks 
run-in period 
(metformin 
+ Liraglutide 
1.8mg)
After Liraglutide 1.8 mg : estimated change +0.02% ↓ from 
baseline
 
 · 271 Pts completed
After insulin detemir + Liraglutide 1.8 mg : estimated change 
-0.51% ↓ from baseline
 
2. SBP:  
After Liraglutide 1.8mg: -3.13 mmHg  
After insulin detemir + Liraglutide 1.8 mg: -1.65 mmHg  
3. GI events:  
· Female: 45.2%
Number of patients reporting GI events in each group:  
 Liraglutide
insulin detemir + 
Liraglutide
 
Nausea 9 6  
Diarrhea 11 19  
· T2D duration  Nasopharyngitis 30 23  
 Mean (SD): 8.3 ± 
5.9Years  
 
 
Headache 13 10  
Lipase increased 6 18  
· Mean(SD)Age: 57 ± 
9.6 years
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7 De wit et al. [28]
 
RCT Single center 
open-label
26 weeks
· 50 Pts randomized
· Liraglutide 1.8 mg/
day added on Insulin 
(pts number 26)
Metformin, 
Sulfonylurea or 
Sulfonylurea and 
metformin.
1. HbA1c:  
Before: mean SD 7.4 ± 0.6%  
After Liraglutide 1.8 mg added on Insulin: estimated change 
-0.77% from baseline 
 
 · 47 Pts completed
After insulin: estimated change +0.01% from baseline  
  
2. SBP:  
After Liraglutide 1.8 mg added on Insulin: -7.0 mmHg ↓ from 
baseline.
 
After insulin: -3.0 mmHg 
· Male: 62%
· Insulin: (pts number 
24)
3. GI events:  
· Female: 38%
Number of patients reporting GI events in each group:  
 Liraglutide insulin glargine  
Nausea 11 3  
Diarrhea 10 6  
· T2D duration
Vomiting 6 1  
Dyspepsia 20 1  
Mean(SD): 7.9 ± 6.0 Years Constipation 14 2  
 
  
Nasopharyngitis 8 7  
  · Mean(SD)
Age: 58 ± 9 years
Headache 10 6  
Decreased appetite 24 2  
Abdominal pain 9 1  
8 Dungan et al. [29]
RCT Multicenter 
Multinational open-
label
26 weeks
· 599 Pts randomized
· Liraglutide: 1.8 mg/
day. (pts number 300)
 
 
 
metformin (≥ 1500 
mg/day)
1. HbA1c:  
 
Before: baseline 7.0-10.0%, mean SD 8.1 ± 0.8%
 
 
 
·538 Pts completed
After Liraglutide: estimated change -1.36% from baseline  
After Dulaglutide: estimated change -1.42% from baseline.  
 
 
 
 · Dulaglutide 1.5 mg/
week (pts number 299)
2. SBP:  
After Liraglutide: -2.82 mmHg ↓ from baseline.  
· Male: 48% After Dulaglutide: -3.36 mmHg ↓ from baseline.  
· Female: 52%  3. GI events:  
 
 · T2D duration: 7.2 ± 
5.4 Years
 
 
 
 
 
 
 
 
 
 
 
Number of patients reporting GI events in each group:  
 Liraglutide Dulaglutide  
Nausea 54 61  
· Mean (SD)Age: 56.65 ± 
9.6 years
Diarrhea 36 36  
 
 
 
 
 
 
 
Vomiting 25 21  
Dyspepsia 18 24  
Constipation 17 11  
Nasopharyngitis 21 23  
Headache 25 22  
Decreased appetite 20 16  
Lipase increased 9 11  
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D’Alessio et 
al. [30]
RCT Multicenter 
Multinational open-
label
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 weeks
· 978 Pts randomized
 
 
· Liraglutide: 1.8 mg/
day. (pts number 470)
 
 
 
 
metformin at a 
minimum dose of 1 
g/day, alone or in 
combination with 
sulphonylurea, 
glinides or a dipeptidyl 
peptidase-4 inhibitor for 
>3 months.
1. HbA1c:  
Before: mean SD 9.0 ± 1.1%  
After Liraglutide 1.8 mg: estimated change -1.79% from 
baseline 
 
After insulin glargine: estimated change -1.94% from baseline  
2. SBP:  
After Liraglutide: -3.1 mmHg ↓ from baseline.  
After insulin glargine: no change.  
· Male: 54.4%
  · insulin glargine: 
(pts number 474)
 
3. GI events:  
Number of patients reporting GI events in each group:  
· Female: 45.6%  Liraglutide insulin glargine  
 
 
 
· T2D duration 
 
 
 
 
Nausea 146 13  
Diarrhea 62 18  
Vomiting 46 8  
Dyspepsia 25 4  
 · Mean (SD): 9 ± 6 Years
 
 
 
Constipation 26 6  
· Mean (SD) Age: 57 ± 
9 years
Nasopharyngitis 35 38  
Headache 29 24  
10 Feinglos et al. [31]
RCT Multicenter 
double-blind USA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 weeks
· 210 Pts randomized
 
 
· Liraglutide 0.045 
mg/day: (pts number 
37)
 
 
None 
1. HbA1c:  
Before: mean SD 7.0 ± 1.2%  
After Liraglutide:  
0.045 mg/day: estimated change +1.28% from baseline  
· 179 Pts completed
 
 
 
 0.225 mg/day: estimated change +0.86% from baseline  
· Liraglutide 0.225 
mg/day 
0.45 mg/day: estimated change +0.22% from baseline  
 0.6 mg/day: estimated change +0.16% from baseline  
(pts number 35) 0.75 mg/day: estimated change +0.30% from baseline  
 After Metformin: estimated change +0.09% from baseline  
·Male: 40%
 · Liraglutide 0.45 mg/
day: (pts number 33)
 
2. GI events:  
Number of patients reporting GI events in each group:  
· Female: 60%
 
 
 Lira groups Metformin  
 
 
· Liraglutide 0.6 mg/
day (pts number 34)
 
 
n:176  n:34  
Nausea 7 2  
 
· T2D duration 
Vomiting 4 1  
 
 
 
 
 
 
 
 
 
· Mean(SD): 4.7 ± 4.8 
Years
 
· Mean(SD)Age: 53.5 ± 
8.8 years
· Liraglutide 0.75 mg/
day: (pts number 37)
 
· Metformin 1000 
mg twice/day(pts 
number 34)
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11 Garber et al. [32]
RCT Multicenter 
double-blind
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 week
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
· 746 Pts randomized
 
· Liraglutide: 1.2 mg/
day. (pts number 251)
None 
1. HbA1c:
Before: mean SD 8.3 ± 1.1%
After Liraglutide 1.2 mg : estimated change -0.84% from baseline 
· 487 Pts completed
 
 
 After Liraglutide 1.8 mg : estimated change -1.14% from baseline 
 After Glimepiride: 8 mg/day: estimated change -0.51% from baseline.
· Male: 50%
 Liraglutide: 1.8 mg/
day. (pts number 247)
 
 
2. SBP: 
 Female: 50% After Liraglutide 1.2 mg: -2.1 mmHg 
·T2D duration: 5.3 ± 5.2 
Years
After Liraglutide 1.8 mg: -3.6 mmHg ↓ from baseline.
After Glimepiride: 8 mg/day: -0.7mmHg ↓ from baseline.
· Mean(SD)Age: 53.0 ± 
10.9 years
 
 
 
 
 
 
 
 
 
 
 Glimepiride: 8 mg/
day (pts number 248)
 
 
 
 
 
 
 
 
 
 
 
3. GI events:
Number of patients reporting GI events in each group:
 
Liraglutide 
1.2 mg
Liraglutide 1.8 mg Glimepiride 
Nausea 69 72 21
Diarrhea 39 46 22
Vomiting 31 23 9
Nasopharyngitis 17 9 13
Headache 27 18 23
Constipation 21 28 12
 Flatulence 4 13 4
12 Garber et al. [33]
RCT Multicenter 
*Participants 
completing the 
1-year randomized, 
double-blind, 
double-dummy 
period (Garber et 
al, 2009) could 
continue open-
label treatment for 
an additional year
2 years (104 
week)
· 746 Pts randomized
 
· Liraglutide: 1.2 mg/
day. (pts number 110) 
 
 
 
None
1. HbA1c:
Before: mean SD 8.0 ± 1.0%
· 440 Pts entered the 
extension at 52 weeks
 
After Liraglutide 1.2 mg : estimated change -0.9% from baseline 
After Liraglutide 1.8 mg : estimated change -1.1% from baseline 
After Glimepiride: 8 mg/day: estimated change -0.6% from baseline.
 321 Pts completed 104 
weeks 
 
 
 
 Liraglutide: 1.8 mg/
day. (pts number 114)
 
 
2. SBP: 
After Liraglutide 1.2 mg: -1.35 mmHg ↓ from baseline.
After Liraglutide 1.8 mg : -2.37 mmHg 
After Glimepiride: 8 mg/day: -0.49 mmHg 
Male: 51.6%·  3. GI events:
 Female: 48.4%
Glimepiride: 8 mg/
day (pts number 97)
Number of patients reporting GI events in each group:
T2D duration: 4.6 ± 4.9 
Years
 
Liraglutide 
1.2 mg
Liraglutide 1.8 mg Glimepiride 
 · Mean(SD)Age: 53.5 ± 
9.6 years
Nausea 72 75 21
Diarrhea 44 48 23
Vomiting 33 25 10
Nasopharyngitis 23 16 18
Headache 28 18 23
Constipation 21 29 12
Flatulence 4 13 5
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13 Gough et al. [34]
RCT Multicenter 
Multinational open-
label
52 weeks
· 1663 Pts randomized
 
· Liraglutide 1.8 
mg/day
 
metformin ± 
pioglitazone
1. HbA1c:
Before: mean SD 8.3 ± 0.9%
· 1311 Pts completed
(pts number 414) After Liraglutide: estimated change -1.24% from baseline 
· Insulin Degludec 
100 U/ml: (pts number 
413)
After Insulin Degludec: estimated change -1.40% from baseline 
After IDegLira: estimated change -1.84% from baseline 
2. SBP: 
- No significant difference in systolic blood pressure between Liraglutide and IDegLira.
- The mean change between IDegLira and insulin degludec was −1.54 mmHg.
· Male: 50.3%  3. GI events:
 Female: 49.7%
· (IDegLira) Insulin 
degludec 100 U/
ml plus Liraglutide 
3.6mg/m(pts number 
833)
The most frequently reported AEs were headache, nausea, diarrhoea, vomiting, 
nasopharyngitis and upper respiratory tract infection.
· T2D duration   
Mean (SD): 6.9 ± 5.5 
Years
· Mean (SD) Age: 55 ± 
9.9 years
  
14 Kaku et al. [35]
RCT Japan double-
blind
24 weeks
· 264 Pts randomized
 
· Liraglutide 0.6 mg/
day: (pts number 88)
 
Sulphonylureas 
(glibenclamide, 
glicazide or 
glimeprimide)
1. HbA1c:
Before: mean SD 8.42 ± 0.91%
241 Pts completed
· Liraglutide 0.9 mg/
day (pts number 88)
After Liraglutide 0.6 mg/day: estimated change -1.46% from baseline 
After Liraglutide 0.9 mg/day: estimated change -1.56% from baseline 
After Placebo: estimated change -0.40% from baseline 
  2. SBP: 
 · Male: 64%
 Placebo(pts number 
88)
Systolic blood pressure did not change in any of the treatment groups during the 
treatment period.
 
· Female: 36%
3. GI events:
More subjects in the two Liraglutide groups reported gastrointestinal adverse events 
during the first 4 weeks
· T2D duration 
Mean(SD): 10.3 ± 7.0 
Years
· Mean(SD)Age:
59.7 ± 10.4 years
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15 Kaku et al. [36]
RCT Japan open-
label
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 weeks
· • 360 Pts 
randomized
· Liraglutide 0.9 mg/
day(pts number 240)
single OAD (glinide, 
metformin, 
 α-glucosidase inhibitor 
or thiazolidinedione)
1. HbA1c:
 • 332 Pts completed
Before: mean SD 8.1 ± 0.8%
 
 
 
After Liraglutide 0.9 mg/day: estimated change -1.21% from baseline 
After Additional OAD: estimated change -0.94% from baseline 
 Additional OAD 
(DPP-4 inhibitor, SU, 
glinide, metformin, 
α-glucosidase inhibitor 
or thiazolidinedione) 
(pts number 120)
  
  2. SBP: 
 · Male: 72.8%  After Liraglutide: -4.0 mmHg ↓ from baseline.
· Female: 27.2%  After Additional OAD: -3.91 mmHg ↓ from baseline.
 
 · T2D duration
 3. GI events:
 Number of patients reporting GI events in each group:
 
 
Mean(SD): 8.02 ± 6.04 
Years
  Liraglutide Additional OAD  
 Nausea 31 4  
 Diarrhea 20 9  
 Constipation 44 12  
 · Mean(SD)Age: 59.5 ± 
11.1 years
 Nasopharyngitis 89 47  
 Headache 12 4  
 Abdominal pain 19 1
16 Lane et al. [37]
RCT Single center 
open-label USA
24 weeks
· 37 Pts randomized
· Liraglutide 1.2mg or 
1.8mg per day: (pts 
number 21)
 
 
>100 units of insulin 
daily with or without 
metformin
1. HbA1c:
 · Male: 46% Before: mean SD 8.1 ± 0.8%
· Female: 54% After Liraglutide: estimated change -0.65% from baseline 
 
· T2D duration
After Insulin up-titration: estimated change -0.39% from baseline
 
· Intensive insulin 
up-titration only: (pts 
number 16)
2. GI events:
 Mean(SD): 17.1 ± 7.1 
Years
In Liraglutide group 24% experiencing mild to moderate nausea in the first 4 weeks 
which resolved by 12 weeks, and only one subject experienced vomiting.
Mean(SD)Age: 59.7 ± 
10.8 years
 
17 Li et al. [38]
RCT China open-
label
 
16 weeks
· 90 Pts randomized
· Liraglutide 1.2 mg/
day Added on Insulin: 
(pts number 42)
Insulin injections for 
at least 3 months at 
a dose of at least 10 
U/day
1. HbA1c:
Before: mean SD 8.7 ± 0.9%
After Liraglutide 1.2 mg/day Added on Insulin: estimated change -1.9% from 
baseline 
  After Insulin-increasing dose: estimated change -1.77% from baseline.
 · 84 Pts completed  2. GI events:
· Insulin-increasing 
dose: (pts number 42)
GI events (diarrhoea, constipation, nausea and vomiting) are most frequently reported 
in Liraglutide-added group.
· Male: 59.5%
· Female: 40.5%
· T2D duration 
Mean(SD): 9.0 ± 3.6 Years
· Mean(SD)Age: 52 ± 
10.2 years
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18 Lind et al. [39]
RCT Multicenter
double blind
24 weeks
· 124 Pts randomized
 
 
· Liraglutide 1.8mg/
day: (pts number 64)
Multiple daily insulin 
injections with or 
without Metformin.
1. HbA1c:
Before: mean SD 8.1 ± 0.8%
After Liraglutide: estimated change -1.55% from baseline 
After Placebo: estimated change -0.42% from baseline 
· 122 Pts completed
 
· Placebo : (pts 
number 60) 
 
 
 
 
 
 
2. SBP: 
After Liraglutide: -5.69 mmHg ↓ from baseline.
 · Male: 64.6%
After Placebo: +1.98 mmHg ↑ from baseline.
 
3. GI events:
· Female: 35.4% Number of patients reporting GI events in each group:
 
 · T2D duration
 Liraglutide Placebo  
GI events 30 8  
Nausea 21 1  
Mean(SD): 17.1 ± 7.8 
Years
Diarrhea 5 3  
· Mean(SD)Age: 63.6 ± 
7.9 years
 
19
Madsbad et 
al. [62]
RCT double blind 12 weeks
· 193 Pts randomized
· Liraglutide 0.045 
mg/day: (pts number 
26)
None
1. HbA1c:
Before: mean SD 7.6%
After Liraglutide 0.045 mg/day: estimated change +0.25% from baseline 
 · 122 Pts completed
After Liraglutide 0.225 mg/day: estimated change -0.34% from baseline
After Liraglutide 0.45 mg/day: estimated change -0.30% from baseline
· Liraglutide 0.225 
mg/day (pts number 
24)
After Liraglutide 0.60 mg/day: estimated change -0.70% from baseline
After Liraglutide 0.75 mg/day: estimated change -0.75% from baseline
After Glimepiride: estimated change -0.74% from baseline
· Liraglutide 0.45 mg/
day: (pts number 27)
After Placebo: estimated change -0.42% from baseline 
 
· Male: 64.6%
· Female: 35.4%
2. GI events:
Number of patients reporting GI events in each group:
 
Liraglutide 
groups 135 pts 
Placebo Glimepiride
 
· T2D duration
· Liraglutide 0.60 mg/
day(pts number 30) 
Nausea 10 1 0
 
 Liraglutide 0.75 mg/
day (pts number 28)
Diarrhea 5 0 0
Vomiting 3 0 0
Mean(SD): 17.1 ± 7.8 
Years
Constipation 3 0 0
· Mean(SD)Age: 56.6 
years
 
 
· Glimepiride 1-4mg 
(pts number 26)
 
 
· Placebo(pts number 
29)
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20 Marre et al. [40]
RCT Multicenter 
Multinational 
double-dummy
26 weeks
· 1041 Pts randomized
· Liraglutide: 0.6 mg/
day. (pts number 233) 
 
Glimepiride (2– 4 
mg/day)
1. HbA1c:
Before: mean SD 8.4 ± 1.0%
After Liraglutide 0.6 mg: estimated change -0.6% from baseline
After Liraglutide 1.2 mg: estimated change -1.08% from baseline
· 894 Pts completed
· Liraglutide: 1.2 mg/
day. (pts number 228)
 
 
 
After Liraglutide 1.8 mg: estimated change -1.13% from baseline
 
 
 
After Placebo: estimated change +0.23% from baseline 
After Rosiglitazone: estimated change -0.44% from baseline.
· Male: 49.2% 2. SBP: 
 · Female: 50.8%
 Liraglutide: 1.8 mg/
day. (pts number 234)
After Liraglutide 1.2mg OR 1.8mg: -2.6 to -2.8 mmHg ↓ from baseline.
After Placebo OR Rosiglitazone: -0.9 to -2.3 mmHg ↓ from baseline.
· T2D duration
3. GI events:
The percentage of GI events With Liraglutide 1.2mg which was the highest:
Mean(SD): 6.5 Years
· Placebo: (pts number 
114)
Nausea 10.50%   
Diarrhea 7.90%   
 Mean(SD)Age: 56 ± 10
· Rosiglitazone: 4 mg/
day. (pts number 232)
Vomiting 4.40%  
21 Mathieu et al. [41]
RCT Multicenter 
Multinational 
Multinational open-
label
26 weeks
· 177 Pts randomized
· Liraglutide 1.8 mg/
day: (pts number 88)
insulin degludec (IDeg) 
once daily + metformin
1. HbA1c:
Before: mean SD 7.7 ± 0.7%
After Liraglutide: estimated change -0.74% from baseline 
 · 151 Pts completed
 Insulin Aspart once 
daily: (pts number 89)
After Insulin Aspart: estimated change -0.39% from baseline
2. GI events:
Number of patients reporting GI events in each group:
 Liraglutide Insulin Aspart  
· Male: 65.6%  Nausea 18 0  
 · Female: 34.4%  Diarrhea 9 0  
· T2D duration  Vomiting 5 0  
Mean(SD): 12.3 ± 6.4 
Years
 Nasopharyngitis 9 11  
· Mean(SD)Age: 61 ± 
9.1 years
 Lipase increase 6 0  
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22 Meier et al. [42]
RCT Multicenter 
open-label 
Germany
8 weeks
· 142 Pts randomized
· Liraglutide: 1.2 mg/
day. (pts number 47)
insulin glargine
1. HbA1c:
Before: mean SD 7.8 ± 0.8%
After Liraglutide 1.2 mg: estimated change -0.7% from baseline
 · 136 Pts completed After Liraglutide 1.8 mg: estimated change -0.7% from baseline
 After Lixisenatide: estimated change -0.6% from baseline 
· Male: 74%
· Liraglutide: 1.8 mg/
day. (pts number 47)
 
 · Female: 26%
2. SBP: 
After Liraglutide 1.2 mg: -0.5 mmHg ↓ from baseline.
 Lixisenatide 20 µg/
day (pts number 48)
After Liraglutide 1.8 mg: -2.5 mmHg ↓ from baseline.
 Mean (SD): 11.4 ± 7.4 
Years
After Lixisenatide: +0.4 mmHg ↑ from baseline.
3. GI events:
Number of patients reporting GI events in each group:
 · Mean (SD) Age: 61.8 ± 
8.2 years.
 
Liraglutide 
1.2mg
Liraglutide 1.8mg Lixisenatide
Nausea 8 11 9
Diarrhea 4 5 3
Vomiting 2 5 5
Constipation 5 3 0
Abdominal pain 2 1 3
Abdominal distention 7 4 3
Lipase increase 5 1 0
23
Miyagawa et 
al. [43] 
RCT Multicenter 
Japan
26 week
· 487 Pts randomized
 
· Liraglutide: 0.9 mg/
day. (pts number 137)
 
 
None
1. HbA1c:
Before: mean SD 8.14% ± (0.81%)
462 Pts completed
 
After Liraglutide: estimated change -1.33%
After Dulaglutide: estimated change -1.43%
After placebo: estimated change 0.14%
· Male: 81%
· Dulaglutide: 0.75 
mg/day. (pts number 
280)
 
2. SBP: 
 · Female: 19% After Liraglutide: -2.10 mmHg ↓ from baseline.
· Female: 19% After Dulaglutide: 0.62 mmHg ↓ from baseline.
 · T2D duration: 6.6 ± 
5.6 Years
 · placebo:(pts number 
70) 
 
After placebo: 0.53 mmHg ↑ from baseline.
 3. GI events:
· Mean (SD) Age: 57.4 
± 9.6.
Number of patients reporting GI events in each group: 
 Liraglutide Dulaglutide placebo
Nausea 11 15 1
Diarrhea 5 16 1
Nasopharyngitis 16 37 4
Lipase increased 2 4 0
Decreased appetite 8 2 0
Constipation 8 19 3
Abdo distention 7 6 0
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Nauck et al. [44] 
LEAD2
 
 
 
 
 
 
 
 
RCT Multicenter 
Multinational 
double-blind, 
double- dummy
26 weeks
· 1091 Pts randomized
· Liraglutide: 0.6 mg/
day. (pts number 242)
Metformin
1. HbA1c:
Before: mean SD 8.4 ± 1.0%
After Liraglutide 0.6 mg : estimated change -0.69% from baseline 
After Liraglutide 1.2 mg : estimated change -0.97% from baseline 
· 880 Pts completed
After Liraglutide 1.8 mg : estimated change -1.0% from baseline 
After Glimepiride: estimated change -0.98% from baseline.
· Liraglutide: 1.2 mg/
day. (pts number 241)
After Placebo: estimated change +0.09% from baseline 
· Male: 58.4%
Liraglutide: 1.8 mg/
day. (pts number 242)
 
2. SBP: 
· Female: 41.6% After Liraglutide 0.6 mg: -0.6 mmHg ↓ from baseline.
 T2D duration After Liraglutide 1.2 mg: -3.2 mmHg ↓ from baseline.
 Mean (SD): 11.4 ± 7.4 
Years
 Glimepiride: 4 mg/
day. (pts number 244)
After Liraglutide 1.8 mg: -2.7 mmHg ↓ from baseline.
Mean (SD) Age: 56.6 ± 
9.4 years.
Placebo: (pts number 
122)
After Glimepiride: +0.4 mmHg ↑ from baseline.
After Placebo: -1.8 mmHg ↓ from baseline.
3. GI events:
GI events (nausea, vomiting, and diarrhea) were reported by 35% of the subjects in 
0.6mg Liraglutide group and 40% in 1.2mg and 44% in 1.8mg Liraglutide group, and 
17% in glimepiride and placebo groups. 
25
Nauck et al. 
[45] (A)
RCT Multicenter 
Multinational Open-
label
26 wee
· 404 Pts randomized
· Liraglutide: 1.8 mg/
day. (pts number 202)
Metformin 1000 to 
3000 mg/day
1. HbA1c:
 340 Pts completed
 Lixisenatide: 20mg/
day, 1h prior to 
morning or evening 
meal.
Before: mean SD 8.4% ± (0.8%)
After Liraglutide: estimated change -1.8% with 74.2% of Pts reached <7%.
 
 · Male: 60%
 · Lixisenatide: 
20mg/day, 1h prior to 
morning or evening 
meal. (pts number 202)
After Lixisenatide: estimated change -1.2% with 45.5% of Pts reached <7%.
2. SBP: 
· Female: 40% After Liraglutide: -4.7 mmHg ↓ from baseline.
· T2D duration: 6.4 ± 5.1 
Years
 
After Lixisenatide: -3.5 mmHg ↓ from baseline.
 · Mean (SD) Age: 56 
± 10.3.
3. GI events:
Number of patients reporting GI events in each group:
 Liraglutide Lixisenatide  
Nausea 44 44  
Diarrhea 25 20  
Vomiting 14 18  
Dyspepsia 11 6  
Nasopharyngitis 13 20  
Headache 15 17  
Lipase increased 17 5  
Decreased appetite 13 5  
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Nauck et al. 
[46] (B)
RCT Multicenter 
Multinational 
double-blind for 
Semaglutide open- 
label for the active 
control Liraglutide
12 weeks
· 415 Pts randomized
· Liraglutide: 1- 1.2 
mg/day (n: 45)
2- 1.8 mg/day (n:50)
Diet and exercise 
or metformin 
monotherapy
1. HbA1c:
 341 Pts completed
Before: mean SD 8.1 ± 0.9 %
After Liraglutide: 
1.2 mg/day: estimated change -1.2% from baseline 
  
1.8 mg/day: estimated change -1.3% from baseline 
After semaglutide:
0.1 mg/week: estimated change -0.6% from baseline 
0.2 mg/week: estimated change -0.9% from baseline
0.4 mg/week: estimated change -1.1% from baseline
0.8 mg/week: estimated change -1.4% from baseline
· Male: 64.8% · Semaglutide: 1- 0.1 
mg/week (n:47)
2- 0.2 mg/week (n:44)
3- 0.4mg/week (n49)
4- 0.8 mg/week (n:44)
 5- 1.6 mg/week (n:45)
1.6 mg/week: estimated change -1.7% from baseline
After Placebo: estimated change -0.5% from baseline
· Female: 35.2%  
 · T2D duration 2. SBP
After Liraglutide:
 Mean (SD): 2.6 ± 2.9 
Years
· Placebo (n:46)
1.2 mg/day: -4.9 mmHg ↓ from baseline.
 Mean (SD) Age: 54 ± 
10.1 years
1.8 mg/day: -5.7 mmHg ↓ from baseline.
After semaglutide:
0.1 mg/week: +2.4 mmHg ↑ from baseline.
0.2 mg/week: -3.8 mmHg ↓ from baseline.
0.4 mg/week: -1.8 mmHg ↓ from baseline. 
0.8 mg/week: -6.2 mmHg ↓ from baseline.
1.6 mg/week: -6.2 mmHg ↓ from baseline.
After Placebo: -3.8 mmHg ↓ from baseline.
3. GI events:
Number of patients reporting GI events in each group:
 Lira groups n:95
Sema groups 
n:227
Placebo n:46
Nausea 14 74 2
Diarrhea 9 33 0
Vomiting 10 40 1
Dyspepsia 9 19 1
Nasopharyngitis 3 15 4
Headache 6 22 3
Decreased appetite 2 9 0
Constipation 4 8 0
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27 Pratley et al. [47]
RCT Multinational 
Open-label
26 weeks
· 658 Pts randomized
· Liraglutide: 1.2 mg/
day. (pts number 221)
Metformin (≥ 1500 mg 
daily for ≥ 3 months)
1. HbA1c:
 554 Pts completed
Before: baseline 7.5% to 10.0% , mean 8.5% 
After Liraglutide 1.2 mg : estimated change -1.24% from baseline
After Liraglutide 1.8 mg : estimated change
 -1.50% from baseline 
After Sitagliptin: estimated change -0.90% from baseline.
· Male: 53%  Liraglutide:  
· Female: 47%
1.8 mg/day. (pts 
number 218)
2. SBP: 
  After Liraglutide 1.2 mg: -0.55 mmHg ↓ from baseline.
 · T2D duration: 6.2 ± 
5.1 Years
 After Liraglutide 1.8 mg : -0.72 mmHg ↓ from baseline.
 · Mean(SD)Age: 55.3 
± 9.2
 Sitagliptin: 100 mg/
day (pts number 219)
After Sitagliptin: -0.94 mmHg ↓ from baseline.
3. GI events:
Number of patients reporting GI events in each group:
 
Liraglutide 
1.2 mg
Liraglutide 1.8 mg Sitagliptin
Nausea 46 59 10
Diarrhea 16 25 10
Vomiting 17 21 9
Dyspepsia 7 14 5
Nasopharyngitis 21 28 26
Headache 20 25 22
Decreased appetite 7 12 2
Constipation 10 11 6
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28 Pratley et al. [48]
RCT Multinational 
Open-label 
Extension to Pratley 
et al, 2010
52 weeks
· 497 Pts randomized
· Liraglutide: 1.2 mg/
day. (pts number 155)
metformin 
monotherapy (≥ 1500 
mg/day
1. HbA1c:
Before: baseline 8.4-8.5%
After Liraglutide 1.2 mg : estimated change -1.29% from baseline
· 436 Pts completed
After Liraglutide 1.8 mg : estimated change -1.51% from baseline
After Sitagliptin: estimated change -0.88% from baseline.
· Male: 53%
 Liraglutide: 1.8 mg/
day. (pts number 176)
 
2. SBP:
 · Female: 47% After Liraglutide 1.2 mg: -0.37 mmHg ↓ from baseline.
 · T2D duration: 6.2 ± 
5.1 Years
After Liraglutide 1.8 mg: -2.55 mmHg ↓ from baseline.
 · Mean(SD)Age: 55.3 
± 9.2
 
 
 
 
 
 
 
 
 
 
 
 
 · Sitagliptin: 100 mg/
day (pts number 166)
After Sitagliptin: -1.03 mmHg ↓from baseline.
  
 
 
 
 
 
 
 
 
 
3. GI events:
Number of patients reporting GI events in each group:
 
Liraglutide 
1.2 mg
Liraglutide 1.8 mg Sitagliptin
(Patients) (Patients) (Patients)
Nausea 48 60 12
Diarrhea 20 27 14
Vomiting 18 23 11
Dyspepsia 8 15 5
Nasopharyngitis 27 32 31
Headache 21 29 27
Decreased appetite 8 12 3
 Constipation 10 13 8
29 Pratley et al. [49]
RCT Multicenter 
Multinational open-
label
32 weeks
· 841 Pts randomized · Liraglutide: 1.8 mg/
day. (pts number 406)
 
One or more 
oral antidiabetes 
drugs (metformin, 
thiazolidinedione or 
Sulfonylurea)
1. HbA1c:
 686 Pts completed Before: mean SD 8.16 ± 0.86%
 · Male: 50%
Albiglutide 50mg/
week (pts number 404)
After Liraglutide: estimated change -0.99% from baseline 
After Albiglutide: estimated change -0.78% from baseline 
 · Female: 50%
2. SBP: 
After Liraglutide: less than 1 mmHg ↓ from baseline.
After Albiglutide: less than 1 mmHg ↓ from baseline.
 · T2D duration
3. GI events:
Number of patients reporting GI events in each group:
 Liraglutide Albiglutide  
Mean(SD): 8.3 ± 5.8 Years
Nausea 119 40  
Diarrhea 55 60  
 · Mean(SD)Age: 55.6 ± 
10 years
Vomiting 38 20  
Headache 22 22  
Nasopharyngitis 28 24  
Lipase increase 28 22  
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30
Rosenstock et 
al. [50]
RCT Multicenter 
Multinational
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 weeks + 12 
weeks run-in 
period
· 323 Pts randomized
· Liraglutide: 1.8 mg/
day.  (pts number 161)
Metformin
1. HbA1c:
  Before: mean SD 7.6 ± 0.65%
randomized
1.8 mg/day.  (pts 
number 161)
After Liraglutide: no change from baseline.
 · 222 Pts completed After Liraglutide + insulin detemir: estimated change -0.45% from baseline 
 
 Male: 54.8%
 
Liraglutide: 1.8 mg/
day + insulin detemir. 
(pts number 162)
2. SBP: 
After Liraglutide: -4.89 mmHg ↓ from baseline.
· Female: 45.2%
After Liraglutide + insulin detemir: -2.07 mmHg ↓ from baseline.
3. GI events:
· T2D duration
Number of patients reporting GI events in each group:
 Liraglutide 
Liraglutide + 
insulin detemir
 
Mean(SD): 8.5 ± 5.9 Years Nausea 12 9  
 · Mean (SD) Age: 57 ± 
9.6 years
Diarrhea 14 21  
Vomiting 9 10  
Headache 15 13  
Nasopharyngitis 38 32  
Lipase increase 7 20  
31
Russell-Jones et 
al. [51] LEAD5
RCT Multicenter 
Multinational
26 weeks
· 581 Pts randomized
· Liraglutide: 1.8 mg/
day. (pts number 232)
All in combination with 
metformin (1 g twice 
daily) and glimepiride 
(4 mg once daily)
1. HbA1c:
 · 522 Pts completed Before: mean SD 8.26% ± (0.9%) 
· Male: 55.4% After Liraglutide: estimated change -1.33% 
 · Female: 44.6% After placebo: estimated change -0.24%
 
 · Placebo. (pts 
number 115)
After insulin glargine: estimated change -1.09% 
2. SBP: 
After Liraglutide: -4.0 mmHg ↓ from baseline.
After placebo: -1.4 mmHg ↓ from baseline.
After insulin glargine: 0.54 mmHg ↑ from baseline.
· T2D duration: 9.4 ± 6.1 
Years
 · open-label insulin 
glargine (pts number 
234) (100 IU/ml 
injected once daily)
3. GI events:
 
· Mean(SD)Age: 57.5 ± 
9.8 years
Number of patients reporting GI events in each group:
 Liraglutide placebo insulin glargine
Nausea 32 4 3
Diarrhea 23 6 3
Vomiting 15 4 1
Dyspepsia 15 1 4
Nasopharyngitis 21 10 26
Headache 22 9 13
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32 Seino et al. [52]
RCT Multicenter 
double-blind Japan
14 weeks
· 226 Pts randomized
· Liraglutide 0.1 mg/
day: (pts number 45)
With or without oral 
antidiabetes drug 
monotherapy
1. HbA1c:
 Before: mean SD 8.30%
· 210 Pts completed
After Liraglutide 0.1 mg/day: estimated change -0.79% from baseline 
 Liraglutide 0.3 mg/
day (pts number 46)
 
After Liraglutide 0.3 mg/day: estimated change -1.22% from baseline
· Male: 66.8% After Liraglutide 0.6 mg/day: estimated change -1.64% from baseline
 · Female: 33.2%
· Liraglutide 0.6 mg/
day: (pts number 45)
After Liraglutide 0.9 mg/day: estimated change -1.85% from baseline
· T2D duration  After placebo: estimated change +0.09% from baseline
Mean(SD): 7.6 ± 5.4 Years
· Liraglutide 0.9 mg/
day (pts number 44)
2. GI events:
Mean(SD)Age: 57.3 years
 Placebo (pts number 
46)
Incidences of gastrointestinal disorders were placebo, 24%; Liraglutide 0.1 mg/day, 
18%; 0.3 mg/day, 15%; 0.6 mg/day, 31%; 0.9 mg/day, 30%.
33 Seino et al. [53]
RCT Multicenter 
double-blind Japan
52 weeks 
· 264 Pts randomized
· Liraglutide 0.6 mg/
day: (pts number 88)
sulfonylurea 
(glibenclamide, 
gliclazide or 
glimepiride)
1. HbA1c:
 · 210 Pts completed
 Liraglutide 0.9 mg/
day (pts number 88)
Before: mean SD 8.82 ± 0.91 %
Male: 64%  
 Female: 36%  After Liraglutide 0.6 mg/day: estimated change -1.09% from baseline
· T2D duration  After Liraglutide 0.9 mg/day: estimated change -1.28% from baseline
 · After placebo: estimated change -0.06% from baseline
 Mean(SD): 10.3 ± 7.0 
Years
Placebo (pts number 
88)
2. GI events:
 Mean(SD)Age: 59.7 ± 
10.4 years
 Number of patients reporting GI events in each group:
   
Liraglutide 
0.6 mg
Liraglutide 0.9 mg placebo
Diarrhea 4 6 6
  Constipation 6 7 3
34 Seino et al. [54]
RCT Multicenter 
double-blind Japan
36 weeks 
· 257 Pts randomized
 
· Liraglutide 0.9 mg/
day(pts number 127)
Insulin therapy (basal 
insulin, premixed 
insulin or basal–bolus 
regimen)
1. HbA1c:
 · 246 Pts completed Before: mean SD 8.8 ± 0.9 %
· 246 Pts completed After Liraglutide 0.9 mg/day: estimated change -1.68% from baseline
 · Male: 56% After placebo: estimated change -0.88% from baseline
· Female: 44%
 
· Placebo (pts number 
130)
2. SBP
After Liraglutide: −3.12 mmHg ↓ from baseline.
After placebo: +2.46 mmHg ↑ from baseline.
3. GI events:
Number of patients reporting GI events in each group:
  Liraglutide placebo  
· T2D duration 
 
Nausea 14 7  
Diarrhea 15 4  
· Mean (SD): 14.51 ± 8.73 
Years
Dyspepsia 7 0  
 
 · Mean (SD) Age: 60.5 ± 
11.2 years
 
Constipation 15 2  
Headache 8 6  
Nasopharyngitis 55 40  
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35 Tanaka et al. [55]
RCT Japan open-
labele
24 weeks
· 47 Pts randomized
· Liraglutide 0.9 mg/
day (pts number 22)
 
 
None 
1. HbA1c:
 · 46 Pts completed Before: mean SD 7.85 ± 0.7%
· Male: 63% After Liraglutide: estimated change -0.80% from baseline
· Female: 37% After metformin: estimated change -0.95% from baseline
· T2D duration
· Metformin 1500 
mg/day or more (pts 
number 24)
2. SBP
 Mean(SD): 5.15 ± 4.0 
Years
No significant change in systolic blood pressure. 
Mean(SD)Age: 53 ± 11 
years
3. GI events 
Constipation was more frequent in the Liraglutide group.
Diarrhea more frequent in the metformin group.
36
Vanderheiden et 
al. [56]
RCT Single-center 
double-blind
6 Month 
· 71 Pts randomized
· Liraglutide: 1.8 mg/
day. (pts number 35)
Total daily dose of 
insulin exceeding 1.5 
U/kg/d
1. HbA1c:
 · 66 Pts completed
 Insulin mean (SD): 
247 ± 95.1U/d
Before: mean SD 9.0% ± 1.2%
· Male: 37%  After Liraglutide: estimated change -1.1%
 · Female: 63%
· Placebo: (pts number 
36)
 
After Placebo: No change 0% 
 · T2D duration: 17.9 ± 
8.4Years
2. SBP: 
After Liraglutide: -1 mmHg ↓ from baseline.
 Mean (SD) Age: 54.2 
± 7.4.
After Placebo: -3 mmHg ↓ from baseline.
3. GI events:
In Liraglutide: 13 of 35 adverse events 
In placebo: 13 of 36 adverse events
37 Vilsboll et al. [57] RCT double-blind 14 weeks 
· 165 Pts randomized
· Liraglutide 0.65 mg/
day (pts number 40) 
None
1. HbA1c:
 · 140 Pts completed
 · Liraglutide 1.25 mg/
day: (pts number 42)
Before: mean SD 8.30 %
· Male: 60.7% After Liraglutide 0.65 mg/day: estimated change -0.98% from baseline 
 · Female: 39.3% After Liraglutide 1.25 mg/day: estimated change -1.40% from baseline
· T2D duration
 · Liraglutide 1.90 mg/
day (pts number 41)
After Liraglutide 1.90 mg/day: estimated change -1.45% from baseline
 
· Placebo: (pts number 
40)
After placebo: estimated change +0.29% from baseline
  2. SBP:
· Male: 60.7%
· Liraglutide 1.90 mg/
day (pts number 41)
Systolic blood pressure decreased significantly 
Mean(SD): 5.5 ± 9.8 Years
1.90 mg vs. placebo: −7.9 mmHg [−12.9 to −2.9], P=0.0023; 
1.25 mg vs. placebo: −5.2 mmHg [−10.2 to −0.2], P=0.0417; 
 Mean(SD)Age: 55.8 ± 
9.9 years
0.65 mg vs. placebo: −7.4 mmHg [−12.4 to −2.4], P=0.0041.
3. GI events:
Number of patients reporting GI events in each group:
 
Liraglutide 
groups (n:123)
Placebo (n:40)  
Nausea 9 1  
Diarrhea 26 5  
Vomiting 4 0  
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38 Yang et al. [58]
RCT Multicenter 
Multinational 
double-blind 
double-dummy
16 weeks
· 929 Pts randomized
· Liraglutide: 0.6 mg/
day. (pts number 231)
Metformin (2000 mg 
daily).
1. HbA1c:
Before: mean SD 8.6 ± 1.0%
After Liraglutide 0.6 mg : estimated change -1.14% from baseline 
 · 779 Pts completed After Liraglutide 1.2 mg : estimated change -1.36% from baseline 
· Male: 55.3%
After Liraglutide 1.8 mg : estimated change -1.45% from baseline 
 
· Liraglutide: 1.2 mg/
day. (pts number 233)
After Glimepiride 4 mg: estimated change -1.39% from baseline 
 2. SBP:
In Liraglutide groups: -3 mmHg ↓ from baseline
· Female: 44.7%
 · Liraglutide: 1.8 mg/
day. (pts number 233)
In Glimepiride group: -0.91 mmHg ↓ from baseline
Mean(SD): 7.5 ± 5.5 Years · Glimepiride: 4 mg/
day (pts number 231)
3. GI events:
GI events ( diarrhoea, nausea, vomiting) are most frequently reported in Liraglutide 
groups than in Glimepiride group.· Mean(SD)Age: 53.3 ± 
9.5 years
39 Zang et al. [59]
RCT Multicenter 
open-labele China
26 weeks
· 368 Pts
· Liraglutide: 1.8 mg/
day (pts number 184)
metformin 
monotherapy
1. HbA1c:
Male: 59.6% Before: baseline 8.4-8.5%
Female: 40.4% After Liraglutide: estimated change -1.51% from baseline 
 · T2D duration:
After Sitagliptin: estimated change -0.88% ↓ from baseline.
2. SBP:
After Liraglutide: -4.31 mmHg ↓ from baseline.
After Sitagliptin: -2.76 mmHg ↓ from baseline.
3. GI events:
Number of patients reporting GI events in each group:
 
Liraglutide 
1.8 mg
Sitagliptin  
Nausea 27 1  
Diarrhea 15 4  
Lipase increased 11 8  
Decreased appetite 20 1  
40
Zinman et al. [60] 
LEAD4
RCT Multicenter 
Multinational 
Double-blind
26 weeks
· 533 Pts 
randomized
Liraglutide 1.2 mg/
day (pts number 178)
metformin (1 g twice 
daily)
1. HbA1c:
· 407 Pts 
completed
Liraglutide 1.8 mg/
day (pts number 178)
Before: mean SD 8.6 ± 1.0%
Male: 56.6% After Liraglutide: estimated change -1.1 from baseline.
Female: 43.4% After Liraglutide 1.8 mg: estimated change -1.1 from baseline.
· T2D duration: Mean(SD): 
9 ± 6 Years
Placebo: (pts number 
177)
After Placebo: estimated change -0.8 from baseline.
· Mean(SD) Age: 55 ± 
10 Years
2. SBP:
After Liraglutide: -6.7 ± 1.1 mmHg ↓from baseline.
After Liraglutide 1.8 mg: -5.6 ± 1.1 mmHg ↓from baseline.
After Placebo: -1.1 ± 1.2 mmHg ↓from baseline.
3. GI events:
GI events (diarrhoea, nausea, vomiting) are most frequently reported in Liraglutide 
groups than in placebo. It was reported by 45% in 1.2 mg Liraglutide, 56% in 1.8mg 
Liraglutide and 19% in Placebo.
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that higher doses of Liraglutide are more effective in lowering HbA1c 
levels. Scott [64] states that Liraglutide is dose-dependent when it 
comes to reducing HbA1c levels, postprandial plasma glucose levels, 
and fasting plasma glucose, and that it improves glucose levels over a 
24 h dosage interval.
Based on the results of the included studies, Liraglutide is proven 
to be effective in lowering HbA1c levels as a monotherapy or as 
adjunct treatments to other oral antidiabetes agents or insulin.
Liraglutide was assessed as a monotherapy in 7 trials (10, 11, 12, 19, 
23, 35 and 37). In study (10), Liraglutide showed a greater reduction 
in HbA1c level compared to metformin while in study (35), there 
was no significant difference between them, with the estimated mean 
changes in HbA1c level being- 0.80% for Liraglutide and -0.95% for 
Metformin. However, in both trials (10, 35), the maximum Liraglutide 
dose used was less than 1 mg/day. In addition, when comparing 
Liraglutide to Dulaglutide (23), there was no significant difference 
between them as the estimated change in HbA1c level after 26 weeks 
was- 1.33% for Liraglutide and - 1.43% for Dulaglutide. Studies (11, 
12, and 19), showed that Liraglutide monotherapy reduces HbA1c 
significantly more than Glimepiride monotherapy and more than a 
placebo (37). 12 studies (3, 4, 7, 9, 13, 14, 15, 20, 29, 31, 32 and 33) 
assessed Liraglutide’s efficacy as an adjunct treatment to different oral 
antidiabetes drugs, such as sulphonylureas, dipeptidyl peptidase-4 
inhibitor, and metformin. The results of these studies showed a 
significant reduction in HbA1c levels among Liraglutide groups. In 
addition, Liraglutide was given together with insulin therapy as a 
background treatment in some studies (1, 16, 17, 18, 21, 22, 34, and 
36). These studies showed a significant reduction in HbA1c levels, 
with the mean estimated changes ranging from 0.65% to 1.9% from 
the baseline. Another 12 studies (2, 5, 6, 8, 24, 25, 27, 28, 30, 38, 39, 
and 40) assessed Liraglutide’s efficacy as an adjunct treatments to 
metformin, with metformin being the background treatment in both 
the Liraglutide and control groups. When Liraglutide was compared 
to Liraglutide plus insulin therapy, both arms in combination with 
metformin (2, 6, and 30), Liraglutide plus insulin therapy was 
more effective than Liraglutide, with the estimated mean changes 
in HbA1c levels in these studies (2, 6, and 30) for Liraglutide and 
Liraglutide plus insulin therapy being -0.16% and -1.04%, +0.02% 
and -0.51% and no change and -0.45%, respectively. In addition, 
in study (8), Dulaglutide was more effective than Liraglutide (both 
with metformin), with the estimated mean changes in HbA1c being 
-1.42% and -1.36%, respectively. However, Liraglutide was superior 
to Glimepiride (24 and 38), Lixisenatide (25), and the placebo (40) 
when both arms were given in combination with metformin, with a 
significant reduction in HbA1c levels in the Liraglutide groups and 
the mean estimated changing from -1.0% to -1.8% from the baseline 
in these studies. In studies (5, 27, 28, and 39), Liraglutide was superior 
to Sitagliptin when both were given in combination with metformin, 
with a significant reduction in HbA1c levels in the Liraglutide groups. 
The estimated mean changes in HbA1c levels in the Liraglutide 
groups in these studies were -1.4%, -1.50%, and -1.51 respectively.
The efficacy of Liraglutide on HbA1c has also been proven in 
observational studies. Kesavadev et al. [65] carried out a prospective, 
open label, single arm, and single centre observational study over 24 
weeks to assess the efficacy 1.8 mg of Liraglutide in 195 Indian patients 
with type 2 diabetes. The study results showed a reduction in HbA1c 
level from 8.14% to 6.96% at week 24, with 49.23% of the treated 
patients reaching HbA1c <7.0% and 41.03% reaching HbA1c ≤ 6.5%. 
In addition, Feher et al. [66] performed a real-world observational 
study to assess the efficacy of Liraglutide compared to Lixisenatide 
by utilizing The Health Improvement Network Database, which 
includes electronic medical records for over 13 million patients in the 
United Kingdom. They assessed 579 patients using Liraglutide and 
213 patients using Lixisenatide, all with type 2 diabetes and aged over 
18 years old, and it was found that Liraglutide decreases HbA1c levels 
significantly more than Lixisenatide and that patients are more likely 
to achieve their target HbA1c level with Liraglutide.
Theme 2: Liraglutide and SBP
The overall results of the included studies that measured SBP 
showed a significant reduction in SBP. However, the included studies 
did not assess SBP as a primary end point. In studies comparing 
Liraglutide to GLP-1 receptors agents, Liraglutide was not always 
better at reducing SBP. As GLP-1 receptors agents are known to be 
associated with lowering SBP ≈2 mmHg [67]. Study (8) compared 
Liraglutide with Dulaglutide and the results were -2.82 mmHg 
decreased from the baseline with Liraglutide and -3.36 mmHg 
decreased from the baseline with Dulaglutide. However, in study 
(23), the significant reduction of Liraglutide was more than that of 
Dulaglutide at -2.10 mmHg and -0.62 mmHg, respectively.
Also, when Liraglutide was compared to Semaglutide (26), 
Semaglutide was superior in reducing SBP but without a significant 
difference (-6.2 mmHg from the baseline with Semaglutide and -5.7 
mmHg with Liraglutide). The results of studies (22 and 25), showed 
a superior significant reduction in SBP with Liraglutide compared 
to Lixisenatide. This is also supported by an observational study 
comparing Liraglutide and Lixisenatide. In this observational study, 
the reduction of SBP was greater in the Liraglutide group than the 
Lixisenatide one, but the results were not significantly different [66].
The efficacy of Liraglutide on SBP was also proven in a real-world 
observational study that found that mean SBP reduced from 129.31 
mmHg to 119.59 mmHg [65]. The efficacy of Liraglutide in reducing 
SBP is agreed on by many studies and reviews [34,46,64,68]. However, 
a recent analysis study they suggests that this blood pressure reduction 
effect is more likely to happen in patients with better glycemic control 
while patients with higher HbA1c are more likely to respond with 
glycemic control improvement [69-74]. Therefore, treatment based 
on individualized evaluation is encouraged.
Theme 3: Liraglutide and GI disturbances
It is known that Liraglutide can cause different types of GI 
disturbance as in all included studies the percentage of patients who 
experienced GI events varied from low to high percentages. These 
adverse GI events, especially nausea, are not only seen with Liraglutide 
but with all GLP-1 receptor agonist agents and one possible cause is 
the delayed gastric emptying effect of GLP-1 receptors [75-82]. The 
results of the included studies that compared Liraglutide to a placebo, 
OAD medications, and insulin showed a higher rate of patients 
reporting GI events among the Liraglutide groups. Contrastingly, in 
the studies that compare Liraglutide to GLP-1 receptor agents such as 
Exenatide, Dulaglutide, Lixisenatide, and Semaglutide, the number of 
patients reporting GI events tends to be high in both groups [82-88].
Although GI disturbances are frequently reported with Liraglutide, 
it appears to be dose dependent and transient [46,64,75,89-95]. Less 
cases of GI events were reported in the trials that used a small doses 
of Liraglutide. For example, in study (10), Liraglutide was given in 5 
arms and the given doses were between 0.045 mg to 0.75 mg for 176 
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patients and nausea was reported by 7 patients and vomiting by only 4 
patients. The same situation occurred in study (19), which compared 
135 patients, with 10 of them reporting nausea, 5 reporting diarrhea, 
3 reporting vomiting, and 3 reporting constipation.
It is noticeable that in the studies that initiated a run-in period 
of about 12 weeks prior to randomization (2, 6, and 30), the rate of 
reported GI events was less than in the other studies. This is due to 
dose titration and the transient GI effects of Liraglutide. Most of the 
included studies indicate that the GI disturbances are transient in 
nature and resolved within the first four to eight weeks of Liraglutide 
initiation. Also, to minimize the GI side effects, starting with a small 
dose and gradually increasing the dose is recommended [46,75,96-
103].
Conclusion
Liraglutide is effective in lowering HbA1c levels and maintaining 
it within the normal range. Liraglutide as a monotherapy or in a 
combination with other diabetes treatment showed a significant 
reduction in HbA1c levels in most of the included studies. Liraglutide 
was superior to placebo, metformin, sitagliptin, glimepiride, 
rosiglitazone, exenatide, lixisenatide and albiglutide at HbA1c 
reduction.
Furthermore, beside glycemic control, Liraglutide could lead to 
significant reduction in systolic blood pressure, which can reach up 
to -7.0 mmHg. The gastrointestinal adverse events mostly nausea, 
vomiting, and diarrhea, were also common with Liraglutide use, 
which can affect the continuity of treatment. However, based on the 
included studies, these GI disturbances are transient in nature and 
can be resolved within 4 to 8 weeks of Liraglutide initiation.
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